Logo     Print Page  Close Window


SEC Filings


8-K
FIBROCELL SCIENCE, INC. filed this Form 8-K on 02/05/2018
Entire Document
 


Item 8.01 Other Events.
On February 05, 2018, Fibrocell Science, Inc. (the "Company") issued a press release announcing the Company's submission of an investigational new drug application for FCX-013 for the treatment of moderate to severe localized scleroderma. A copy of the press release is attached hereto as Exhibit 99.1.
On February 05, 2018, Fibrocell Science Inc., posted an updated Corporate Presentation on its website www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits